Stimulants

Emerging methamphetamine industry in Afghanistan ‘worrying’, says new EMCDDA study

Retrieved on: 
Tuesday, November 24, 2020
Psychoactive drugs, Drugs, Stimulants, Euphoriants, Substituted amphetamines, TAAR1 agonists, Dietary Supplements, Ephedrine, Methamphetamine, Ephedra, MDMA, Bakwa District

Lisbon 

Key Points: 


Lisbon 
24.11.2020(News release No11/2020)

  • There are signs that a methamphetamine industry is taking hold in Afghanistan, according to a new report published today by the EU drugs agency (EMCDDA).
  • The paper Emerging evidence of Afghanistans role as a producer and supplier of ephedrine and methamphetamine explores whether the country, renowned for being the world's leading opium producer, has the potential to become a significant producer of methamphetamine.
  • The study is based on interviews with ephedrine and methamphetamine cooks, and other key informants, in the district of Bakwa (Farah province, south-west Afghanistan) in August 2020, as well as on documentary sources and the analysis of high-resolution satellite images.
  • Once produced, the ephedrine is sold to traders from other provinces or directly to local methamphetamine production facilities, where skilled methamphetamine cooks take over.
  • There are also increasing reports of methamphetamine connected with Afghanistan being seized further afield (e.g.
  • If the potential amount of ephedrine produced in Bakwa were converted into methamphetamine locally, the industry could be worth an estimated EUR 203 million in Bakwa alone.
  • Increasing reports of further ephedrine and methamphetamine processing in other Afghan provinces (Nimroz, Herat, Nangarhar), raises concern that the output of the countrys methamphetamine industry could one day potentially rival its sizeable opiate economy.
  • The report notes that there is considerable scope for ephedra crop cultivation in Afghanistan.


(1) Ephedrine is one of the precursor chemicals used to make methamphetamine. For more on other methamphetamine precursors, see the EMCDDA Methamphetamine drug profile.

Emerging evidence of Afghanistan’s role as a producer and supplier of ephedrine and methamphetamine

Retrieved on: 
Tuesday, November 24, 2020
Drugs, Psychoactive drugs, Branches of biology, Dietary Supplements, Stimulants, Ephedra, Afghanistan, European Monitoring Centre for Drugs and Drug Addiction, Methamphetamine

EMCDDA, David Mansfield (lead author), Lisbon, November 2020

Key Points: 
  • EMCDDA, David Mansfield (lead author), Lisbon, November 2020
    This paper provides an analysis of the available data that suggest that a methamphetamine industry is rapidly being established in Afghanistan.
  • The analysis provided is based on information from key informants, documentary sources and the analysis of satellite imagery.
  • The paper also highlights an expanding market for ephedra that links the mountainous central region of Afghanistan to the former deserts of the south-west.
  • The report is the result of research conducted under the EU4Monitoring Drugs (EU4MD) project, funded by the European Commission.

“Sneak Peek”: Taat Reveals First Placements of In-Store Graphics in Select Locations of Ohio Tobacco Retailers

Retrieved on: 
Friday, November 20, 2020
Psychoactive drugs, Cigarettes, Entheogens, Leaves, Native American religion, Tobacco, tAAt, Stimulants, Branches of biology

Further, an average of more than 100 Taat sample requests have been received per day through the Companys TryTaat landing page ( http://trytaat.com ).

Key Points: 
  • Further, an average of more than 100 Taat sample requests have been received per day through the Companys TryTaat landing page ( http://trytaat.com ).
  • The Company has developed Beyond Tobacco, the nicotine-free and tobacco-free base material of Taat, which is its flagship product.
  • Taat is being commercialized under the leadership of an executive team with considerable experience in the tobacco industry throughout North America.
  • In addition to providing distribution of Taat to tobacco retailers in Ohio, we have already established redistribution agreements with several other wholesalers who also predict Taat can sell successfully in this market.

Top 50 Company Reports for the Food, Beverage & Tobacco Industry in 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 19, 2020
Tobacco, Retail, Food, Beverage, Psychoactive drugs, Cigarettes, Entheogens, Leaves, Native American religion, Tobacco, Stimulants

The "Top 50 Reports for Food, Beverage & Tobacco" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Top 50 Reports for Food, Beverage & Tobacco" report has been added to ResearchAndMarkets.com's offering.
  • The Global Top 50 Reports for the Food, Beverage & Tobacco Industry contains a comprehensive report for each of the top 50 companies in the industry (ranked by sales or revenue).
  • Deeply discounted price of bundled industry reports - compared to purchase of individual company reports.
  • Also included, as part of each company report, are extensive industry average reports for financial statements and key ratio reports to which the company results can be compared.

Natural Energy Lozenges Have No Caffeine and No Crash

Retrieved on: 
Thursday, November 19, 2020
Articles, Caffeine, Mutagens, Stimulants, Xanthines, Metabolism, Energy

This article represents the sixth in a series intended to illuminate some of the many elements of Natural Energy Lozenges, "Stacked Nutrition, designed by a Physician."

Key Points: 
  • This article represents the sixth in a series intended to illuminate some of the many elements of Natural Energy Lozenges, "Stacked Nutrition, designed by a Physician."
  • So far, we've explained how Natural Energy Lozenges deliver unprecedented metabolic support of: Blood Flow(1), Concentration(2) and Energy,(3)(4)(5) Sublingually, Ecofriendly, and Guaranteed(6), and today, we're going to explain why common stimulating drugs cause a crash, but Natural Energy Lozenges have no caffeine, and no crash.
  • Natural Energy Lozenges on the other hand work completely differently.
  • (9) (10)
    Natural Energy Lozenges on the other hand, have no caffeine and no crash.

Not Coffee, Not an Energy Drink: Orbit Coffee is Breaking the Mold

Retrieved on: 
Thursday, November 19, 2020
Drinks, Psychoactive drugs, Food and drink, Hot drinks, Crops, Caffeine, Mutagens, Stimulants, Coffee, Energy drink

Orbit has been innovating the energy drink industry by creating a delicious, nutrition-packed, long-lasting beverage that comes as a powdered mix-in.

Key Points: 
  • Orbit has been innovating the energy drink industry by creating a delicious, nutrition-packed, long-lasting beverage that comes as a powdered mix-in.
  • Orbit Coffee offers a distinctive coffee flavor as it is made with real coffee, selected and roasted in Italy.
  • Orbit takes its high-quality powdered coffee and adds sequential carbohydrates, and maca, with 133mg of caffeine per serving, creating a unique type of focused energy.
  • Orbit Coffee prioritizes not just a large initial burst of energy, but lasting effects of focused energy.

Adlon Therapeutics L.P. Announces Two New Publications of Adhansia XR® (methylphenidate HCl) Extended-Release Capsules CII Data

Retrieved on: 
Wednesday, November 18, 2020
Biotechnology, Pharmaceutical, Health, Psychoactive drugs, Drugs, Psychoanaleptics, Stimulants, Phenethylamines, Euphoriants, Nootropics, Ergogenic aids, Methylphenidate, Amphetamine, Purdue Pharma, Boxed warning, Adhansia XR®, Adlon Therapeutics L.P.

Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced two recent online publications of studies related to the efficacy, safety and pharmacokinetics of Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII (investigationally known as PRC-063).

Key Points: 
  • Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced two recent online publications of studies related to the efficacy, safety and pharmacokinetics of Adhansia XR (methylphenidate hydrochloride) extended-release capsules CII (investigationally known as PRC-063).
  • The Full Prescribing Information for Adhansia XR contains a Boxed Warning emphasizing that CNS stimulants, including Adhansia XR, other methylphenidate-containing products, and amphetamines have a high potential for abuse and dependence.
  • Adhansia XR is not appropriate for all patients, and healthcare professionals should work with their patients to determine the most appropriate treatment option.
  • Adhansia XR is contraindicated in patients with a known hypersensitivity to methylphenidate or other components of Adhansia XR.

Vallon Pharmaceuticals Presents Positive Data from Proof-of-Concept Intranasal Human Abuse Study of Its Investigational ADHD Stimulant, ADAIR

Retrieved on: 
Monday, November 9, 2020
Drugs, Psychoactive drugs, Clinical medicine, Euphoriants, Stimulants, Anorectics, TAAR1 agonists, Substituted amphetamines, Nasal administration, Dextroamphetamine, Amphetamine, Tolerability

We are pleased with the results gained from our first human abuse liability study which demonstrated that recreational drug abusers preferred ADAIR less when compared to currently available IR dextroamphetamine, a positive signal when trying to reduce stimulant abuse.

Key Points: 
  • We are pleased with the results gained from our first human abuse liability study which demonstrated that recreational drug abusers preferred ADAIR less when compared to currently available IR dextroamphetamine, a positive signal when trying to reduce stimulant abuse.
  • Additionally, the data give us confidence in the design of our upcoming pivotal intranasal abuse study which will evaluate ADAIR with a larger number of subjects, expected to initiate before year end, commented David Baker, President & Chief Executive Officer of Vallon.
  • The 16-subject proof-of-concept intranasal human abuse study (VAL-103) demonstrated that intranasal administration of manipulated ADAIR was generally well tolerated, with all adverse events considered mild or moderate, and no new safety or tolerability signals identified.
  • In addition, snorting manipulated ADAIR was more unpleasant than snorting crushed dextroamphetamine based on the Subject-Rated Assessment of Intranasal Irritation (SRAII) scale.

Cingulate Therapeutics Presents Results of Pivotal Phase 2 Clinical Trial for Lead ADHD Candidate CTx-1301 at the American Association of Child and Adolescent Psychiatry Annual Meeting

Retrieved on: 
Monday, October 26, 2020
Psychoactive drugs, Stimulants, Phenethylamines, AACAP, Childhood psychiatric disorders, Amphetamine, Methylphenidate, Attention deficit hyperactivity disorder, Pemoline, Child and adolescent psychiatry

These results demonstratedthe comparative bioavailability (bridging) between these two products, confirming the 505(b)(2) pathway.

Key Points: 
  • These results demonstratedthe comparative bioavailability (bridging) between these two products, confirming the 505(b)(2) pathway.
  • The data was presented at the American Association of Child and Adolescent Psychiatry (AACAP) annual virtual meeting October 12-24, 2020.
  • "The data is impressive and will help position Cingulate's CTx-1301 product to achieve rapid market uptake," said Shane J. Schaffer, PharmD, Chairman and CEO of Cingulate Therapeutics.
  • Our Phase 3 trials are designed to further confirm the pharmacokinetic-pharmacodynamic relationship of stimulants for ADHD.

KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting

Retrieved on: 
Thursday, October 22, 2020
Psychoactive drugs, Nootropics, Stimulants, Amphetamine, Methylphenidate, Attention deficit hyperactivity disorder, Dexmethylphenidate, Attention deficit hyperactivity disorder management, Attention deficit hyperactivity disorder controversies

KP415 is KemPharms investigational product candidate for the treatment of attention deficit hyperactivity disorder (ADHD).

Key Points: 
  • KP415 is KemPharms investigational product candidate for the treatment of attention deficit hyperactivity disorder (ADHD).
  • Serdexmethylphenidate (SDX) is KemPharms prodrug of d-methylphenidate (d-MPH).
  • KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder.
  • KemPharms co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles.